Literature DB >> 15842546

Biomarkers and surrogate endpoints.

J K Aronson.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15842546      PMCID： PMC1884846          DOI： 10.1111/j.1365-2125.2005.02435.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  20 in total

1.  Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.

Authors:  Saad A W Shakir; Deborah Layton
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

3.  Psychomotor function and psychoactive drugs. 1980.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

4.  Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

Authors:  H Stass; D Kubitza; J-G Möller; H Delesen
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 5.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention.

Authors:  S Perreault; L Blais; D Lamarre; A Dragomir; D Berbiche; L Lalonde; C Laurier; F St-Maurice; J Collin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

7.  Khat chewing is a risk factor for acute myocardial infarction: a case-control study.

Authors:  A Al-Motarreb; S Briancon; N Al-Jaber; B Al-Adhi; F Al-Jailani; M S Salek; K J Broadley
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

8.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

Authors:  J H S You; F W H Chan; R S M Wong; G Cheng
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

9.  Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.

Authors:  J Davies; A Gavin; M Band; A Morris; A Struthers
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

10.  Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial.

Authors:  H A de Silva; M M D Fonseka; A Pathmeswaran; D G S Alahakone; G A Ratnatilake; S B Gunatilake; C D Ranasinha; D G Lalloo; J K Aronson; H J de Silva
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321
View more
  70 in total

1.  Research priorities in biomarkers and surrogate end-points.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  Monitoring therapy.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

4.  Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.

Authors:  Torbjörn Callréus
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Monitoring for adverse drug reactions.

Authors:  J J Coleman; R E Ferner; S J W Evans
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 6.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 7.  Clinical pharmacology--providing tools and expertise for translational medicine.

Authors:  J K Aronson; A Cohen; L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

8.  Brain-Specific Serum Biomarkers Predict Neurological Morbidity in Diagnostically Diverse Pediatric Intensive Care Unit Patients.

Authors:  Alicia K Au; Michael J Bell; Ericka L Fink; Rajesh K Aneja; Patrick M Kochanek; Robert S B Clark
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

Review 9.  Droplet microfluidics for high-sensitivity and high-throughput detection and screening of disease biomarkers.

Authors:  Aniruddha M Kaushik; Kuangwen Hsieh; Tza-Huei Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-24

Review 10.  Top ten errors of statistical analysis in observational studies for cancer research.

Authors:  A Carmona-Bayonas; P Jimenez-Fonseca; A Fernández-Somoano; F Álvarez-Manceñido; E Castañón; A Custodio; F A de la Peña; R M Payo; L P Valiente
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.